This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.

Volume: 36, Issue: 15_suppl, Pages: 7507 - 7507
Published: May 20, 2018
Abstract
7507 Background: Pola is an antibody-drug conjugate targeting CD79b+ cells in B-NHL. Early results led to FDA breakthrough therapy status and EMA PRIME designation. We now report combined results for safety and efficacy from the randomized r/r FL and DLBCL cohorts of a phase 1b/2 study (ClinicalTrials.gov NCT02257567). Methods: 80 FL and 80 DLBCL transplant-ineligible patients (pts) were randomized 1:1 to pola 1.8 mg/kg + BR (B: 90mg/m2 x 2...
Paper Details
Title
Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL.
Published Date
May 20, 2018
Volume
36
Issue
15_suppl
Pages
7507 - 7507
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.